Generated by AI
RedHill Biopharma Ltd. American Depositary Shares represent ownership interests in RedHill Biopharma Ltd., a specialty biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal diseases, infectious diseases, and oncology. The company’s current portfolio includes marketed products and clinical-stage programs centered on oral therapies and targeted treatments for adult patients and other specialized medical needs. RedHill Biopharma operates across commercial operations and research and development, combining product sales activities with ongoing clinical advancement. Its business is aimed at addressing areas where treatment options can be limited, making it a participant in the broader specialty pharmaceuticals market. RedHill Biopharma Ltd. is headquartered in Tel Aviv, Israel, and its American Depositary Shares provide U.S. investors with a way to access the company through a depositary share structure.
Website21 Ha’arba’a Street
Tel Aviv-Yafo, 6473921
Israel
The latest articles about RDHL.
Detailed price information for Redhill Biophrma ADR (RDHL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Redhill Biophrma ADR (RDHL-Q) from The Globe and Mail including charting and trades.
RedHill Biopharma Ltd. (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq from Ferring Pharmaceuticals. The agreement has an initial 13-year term and automatically renews for successive two-year periods unless either party elects not to renew. RedHill Biopharma Ltd. (NASDAQ:RDHL) paid $12 million upfront, funded from the $18 million […]
Summary of Oct 8's posts. Generated by AI.
Summary of Sep 1's posts. Generated by AI.
--RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals, as part of Ferring’ s ongoing strategic refocusing. We have monetized Talicia for $18 million cash upfront, plus $35 million in...
Summary of Aug 31's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Investors talking about RDHL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.